-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
A few days ago, Beda Pharmaceuticals announced that the company has considered the adoption of the "on the company's H-share issue and listing on the main board of the Stock Exchange of Hong Kong Limited" bill.
founded in 2003 to develop innovative anti-tumor-targeted drugs.
was previously listed on the Shenzhen Stock Exchange in 2016.
close of trading today, Beda Pharmaceuticals reported $133.19, with a total market value of $55 billion.
To this time, Beda Pharmaceuticals has commercialized two drugs, the self-developed EGFR-TKI Ektini (commodity name: Kemina), approved in June 2011 for local late stage or metastasis non-small cell lung cancer with sensitive mutations in the skin growth factor (EGFR) gene; Xcovery co-developed a new generation of ALK inhibitor Nsatini capsule hydrochloric acid (commodity name: Bemena) approved in November 2020 for localized late stage or metastatic non-small cell lung cancer that had previously progressed after treatment with cytocinolone or was resistant to ketinib's insuperable mesotrene lymphoma kinase (ALK).
's latest financial report shows that in January-September 2020, Beda Pharmaceuticals achieved revenue of RMB1,508 million, up 21.25 percent year-on-year, with net profit attributable at RMB514 million, up 158.80 percent year-on-year.
same time, the financial report mentioned that its drug Eccleinist continued to grow steadily through a variety of advantages.
that in 2019, Extini's sales amounted to 1.502 billion yuan, accounting for 96.65 percent of operating income.
, Beda has conducted more than 70 clinical studies on the use of ecstinib.
received the approval certificate, Beda Pharmaceuticals has officially started production of new drugs, which is scheduled to generat revenue by the end of the year.
stable growth in the core varieties of Ektini, the company's other varieties are also expected to usher in a period of intensive harvest.
application for a listing license for Beval Pearl Single Anti-Injection (MIL60) was accepted, and a number of registered clinical studies, such as BPI-D0316II and CM082 Renal Cancer Phase III, proceeded as planned.
